Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the MRC Translational Immune Discovery Unit have identified how rare populations of abnormal cells drive the formation and persistence of fistulas - painful, tunnel-like tracts that develop in around 30% of people with Crohn’s disease - paving the way for targeted treatments.

Partially epithelialised fistula tract
Spatial transcriptomics image showing a partially epithelialised fistula tract – this means parts of the tunnel have grown a new lining, while others have not. This is part of the disordered healing process that occurs in Crohn’s fistulas. Each colour in the image represents a different type of cell.

Crohn’s disease is a long-term disease that affects around 1 in every 650 people, in which parts of the gut become swollen, inflamed, and ulcerated. When ulcers or inflammation in the intestinal wall fail to heal properly, Crohn’s fistulas can form, burrowing into surrounding tissue and sometimes connecting to other organs or the skin. Precisely how these form, grow and persist has remained unclear, and they are very challenging to treat.

In this study, published in Nature, researchers analysed thousands of individual cells from Crohn’s fistulas, comparing them with healthy gut tissue. Using advanced single-cell and spatial analysis techniques, the team, led by the Simmons and Antanaviciute Groups, mapped the precise composition and behaviour of cells within the fistula tracts.

They discovered that fistulas are lined by concentric rings of “rogue” fibroblasts – cells that normally maintain tissue structure – that have become reprogrammed to act like cells involved in early fetal gut development. This out-of-context activity caused fibroblasts near the tract surface to destroy the surrounding tissue, promoting tunnelling, while deeper fibroblasts produced stiff, fibrotic material that stabilised and maintained the tunnels.

 

Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience